158 related articles for article (PubMed ID: 33588455)
1. Prevention and Management of Thrombosis in BCR/ABL-Negative Myeloproliferative Neoplasms.
Falanga A; Marchetti M; Schieppati F
Hamostaseologie; 2021 Feb; 41(1):48-57. PubMed ID: 33588455
[TBL] [Abstract][Full Text] [Related]
2. Risk of thrombosis, hemorrhage and leukemic transformation in patients with myeloproliferative neoplasms: A nationwide longitudinal cohort study.
Hur JY; Choi N; Choi JH; Kim J; Won YW
Thromb Res; 2024 Apr; 236():209-219. PubMed ID: 38461615
[TBL] [Abstract][Full Text] [Related]
3. The Pitfalls of Global Hemostasis Assays in Myeloproliferative Neoplasms and Future Challenges.
Tiu A; Chiasakul T; Kessler CM
Semin Thromb Hemost; 2024 Mar; 50(2):213-223. PubMed ID: 37068511
[TBL] [Abstract][Full Text] [Related]
4. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
Barbui T; De Stefano V
Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
[TBL] [Abstract][Full Text] [Related]
5. The Role of Inflammation and Inflammasome in Myeloproliferative Disease.
Longhitano L; Li Volti G; Giallongo C; Spampinato M; Barbagallo I; Di Rosa M; Romano A; Avola R; Tibullo D; Palumbo GA
J Clin Med; 2020 Jul; 9(8):. PubMed ID: 32707883
[TBL] [Abstract][Full Text] [Related]
6. A Review About the Assessment of the Bleeding and Thrombosis Risk for Patients With Myeloproliferative Neoplasms Scheduled for Surgery.
Andreescu M; Andreescu B
Cureus; 2024 Mar; 16(3):e56008. PubMed ID: 38606222
[TBL] [Abstract][Full Text] [Related]
7. Overview of Myeloproliferative Neoplasms: History, Pathogenesis, Diagnostic Criteria, and Complications.
Tremblay D; Yacoub A; Hoffman R
Hematol Oncol Clin North Am; 2021 Apr; 35(2):159-176. PubMed ID: 33641861
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of Therapeutic Strategies to Reduce the Number of Thrombotic Events in Patients With Polycythemia Vera and Essential Thrombocythemia.
Tremblay D; Kosiorek HE; Dueck AC; Hoffman R
Front Oncol; 2020; 10():636675. PubMed ID: 33665170
[TBL] [Abstract][Full Text] [Related]
9. Whole blood transcriptional profiling reveals highly deregulated atherosclerosis genes in Philadelphia-chromosome negative myeloproliferative neoplasms.
Skov V; Thomassen M; Kjaer L; Larsen MK; Knudsen TA; Ellervik C; Kruse TA; Hasselbalch HC
Eur J Haematol; 2023 Nov; 111(5):805-814. PubMed ID: 37640394
[TBL] [Abstract][Full Text] [Related]
10. Smoking as a contributing factor for development of polycythemia vera and related neoplasms.
Hasselbalch HC
Leuk Res; 2015 Sep; ():. PubMed ID: 26463040
[TBL] [Abstract][Full Text] [Related]
11. Myeloproliferative neoplasms in the adolescent and young adult population: A comprehensive review of the literature.
Goulart H; Masarova L; Mesa R; Harrison C; Kiladjian JJ; Pemmaraju N
Br J Haematol; 2024 Jun; ():. PubMed ID: 38853641
[TBL] [Abstract][Full Text] [Related]
12. Cardiovascular risk in a contemporary cohort of patients with myeloproliferative neoplasms'.
Mehta D; Alimam S; McLornan DP; Henry JA; Ahmed S; Ghosh AK; Tyebally S; Walker JM; Patel R; Amerikanou R; O'Nions J; Wilson AJ; Lambert J; Sekhar M; Chen D
Curr Res Transl Med; 2024 Mar; 72(1):103420. PubMed ID: 38262189
[TBL] [Abstract][Full Text] [Related]
13. The immune landscape in BCR-ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy.
Strickland M; Quek L; Psaila B
Br J Haematol; 2022 Mar; 196(5):1149-1158. PubMed ID: 34618358
[TBL] [Abstract][Full Text] [Related]
14. The role of leukocytes in myeloproliferative neoplasm thromboinflammation.
Liu Y; Wang Y; Huang G; Wu S; Liu X; Chen S; Luo P; Liu C; Zuo X
J Leukoc Biol; 2024 May; 115(6):1020-1028. PubMed ID: 38527797
[TBL] [Abstract][Full Text] [Related]
15. Inflammation as a cause of acute myocardial infarction in patients with myeloproliferative neoplasm.
Tirandi A; Schiavetta E; Maioli E; Montecucco F; Liberale L
World J Cardiol; 2024 Feb; 16(2):58-63. PubMed ID: 38456066
[TBL] [Abstract][Full Text] [Related]
16. Reappraisal of cardiovascular risk factors in patients with chronic myeloproliferative neoplasms.
Krecak I; Verstovsek S; Lucijanic M
Clin Adv Hematol Oncol; 2023 Oct; 21(10):541-548. PubMed ID: 37948590
[TBL] [Abstract][Full Text] [Related]
17. Assessment of Endothelial Dysfunction With Flow-Mediated Dilatation in Myeloproliferative Disorders.
Yildiz A; Güryildirim M; Pepeler MS; Yazol M; Oktar SÖ; Acar K
Clin Appl Thromb Hemost; 2018 Oct; 24(7):1102-1108. PubMed ID: 29683036
[TBL] [Abstract][Full Text] [Related]
18. Acute myocardial infarction in myeloproliferative neoplasms.
Manan MR; Kipkorir V; Nawaz I; Waithaka MW; Srichawla BS; Găman AM; Diaconu CC; Găman MA
World J Cardiol; 2023 Nov; 15(11):571-581. PubMed ID: 38058401
[TBL] [Abstract][Full Text] [Related]
19. Optimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives.
Krecak I; Verstovsek S; Lucijanic M
Ann Hematol; 2024 May; 103(5):1513-1523. PubMed ID: 37665349
[TBL] [Abstract][Full Text] [Related]
20. Retinal Vessel Analysis and Microvascular Abnormalities in Patients with Philadelphia-Negative Chronic Myeloproliferative Neoplasms.
Roszkowska AM; Leanza R; Aragona E; Gargiulo L; Alibrandi A; Arrigo A; Bottaro A; Barone P; Stagno F; Allegra A
J Clin Med; 2024 Apr; 13(8):. PubMed ID: 38673505
[No Abstract] [Full Text] [Related]
[Next] [New Search]
